Bicycle Therapeutics to Present Innovative Cancer Therapies at J.P. Morgan Conference

Bicycle Therapeutics Set to Showcase Innovative Therapeutics at J.P. Morgan Conference

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company headquartered in Cambridge, England, is poised to present its groundbreaking developments in therapeutics at the 43rd Annual J.P. Morgan Healthcare Conference. Scheduled for January 14 at 5:15 p.m. PT, the presentation will highlight the company’s pioneering work utilizing its proprietary Bicycle® peptide technology. This technology is distinguished by its fully synthetic bicyclic peptides, which are tailored to enhance binding affinity and selectivity for their targets. Following the presentation, a Q&A session will allow for further engagement with stakeholders, with the entire event available via a live webcast on the company’s investor website.

Central to Bicycle’s mission is the development of a novel class of medicines aimed at addressing unmet medical needs, particularly in oncology. Among its promising candidates, the company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin Conjugate that specifically targets the tumor antigen Nectin-4. This therapeutic innovation is complemented by BT5528, which aims at EphA2, a historically challenging target in cancer treatment, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® that also targets Nectin-4 while activating CD137 to enhance immune response against tumors. These developments underscore Bicycle Therapeutics’ commitment to creating high-affinity and selective treatments that could revolutionize current cancer therapies.

In addition to its oncology-focused initiatives, Bicycle Therapeutics is exploring Bicycle Radionuclide Conjugates (BRC®) for potential applications in radiopharmaceuticals. The company is also actively seeking partnerships to broaden the scope of its technologies beyond cancer treatment, signaling a strategic pivot towards addressing a wider array of diseases that remain inadequately served by existing therapies. With a dual presence in the UK and Massachusetts, Bicycle Therapeutics is well-positioned to lead the charge in innovative drug development.

The upcoming J.P. Morgan Healthcare Conference represents a significant opportunity for Bicycle Therapeutics to showcase its advancements in therapeutic technology and engage with investors and industry experts. By leveraging its proprietary Bicycle® technology, the company aims to make a lasting impact in the realm of pharmaceuticals, particularly for patients facing challenging medical conditions. For further information on the company’s initiatives, stakeholders are encouraged to visit their website at www.bicycletherapeutics.com.